

- comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. *Arthritis Rheum.* 2001; 44: 180-5.
21. Wanders A, Heijde DVD, Landewé R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized The trial. *Arthritis Rheum.* 2005; 52: 21054.
 22. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. *Arthritis Rheum.* 1996; 39: 2004-12.
 23. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. *Arthritis Rheum.* 2005; 52: 21197.
 24. Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: term safety in 23 458 patients from global patient trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. *Ann Rheum Dis.* 2013; 72: 517-24.
 25. Lukas C, Landewé R, Sieper J, et al. Assessment of SpondyloArthritis international Society. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. *Ann Rheum Dis.* 2009; 68: 18-24.
 26. Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinic response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis. *Ann Rheum Dis.* 2004; 63: 665-70.
 27. Bennett AN, McGonagle D, O'Connor P, et al. Severity of baseline magnetic resonance imaging - evident sacroiliitis and HLA - B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. *Arthritis Rheum.* 2008; 58: 3413-8.
 28. Feldtkeller E, Khan MA, van der Heijde D, et al. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. *Rheumatol Int.* 2003; 23: 61-6.
 29. Reveille JD, Sims AM, Danoy P, et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. *Nat Genet.* 2010; 42: 123.
 30. Laval SH, Timms A, Edwards S, et al. Whole-genome screening in ankylosing spondylitis: evidence of non-MHC genetic-susceptibility loci. *Am J Hum Genet.* 2001; 68: 918-26.
 31. Reveille JD, Ball EJ, Khan MA. HLA-B27 and genetic predisposing factors in spondyloarthropathies. *Curr Opin Rheumatol.* 2001; 13: 265-72.
 32. Chou CT, Pei L, Chang DM, et al. Prevalence of rheumatic diseases in Taiwan: a population study of urban, suburban, rural differences. *J Rheumatol.* 1994; 21: 3026.
 33. Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. *Arthritis Rheum.* 2003; 48: 1126-36.
 34. Yurdakul O, Rezvani A. Can ultrasound be an assessment tool for sagittal spine mobility and bony expansion in patients with ankylosing spondylitis?. *Medicine* 2018; 97: 39.
 35. Maksymowych WP, Chiowchanwisawakit P, Clare T, et al. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. *Arthritis Rheum.* 2009; 60: 93-102.
 36. Bennett AN, McGonagle D, O'Connor P, et al. Severity of baseline magnetic resonance imaging - evident sacroiliitis and HLA - B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. *Arthritis Rheum.* 2008; 58: 3413-8.